Aktienanalyse zu ImageneBio Inc (IMA)IMAImageneBio Inc

ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis. It operates in the Healthcare sector.

ImageneBio Inc is currently a hold. The stock is priced at $4.09, significantly below its 52-week high of $8.84, indicating potential upside. However, the company has reported a net loss of $10.6 million for Q1 2026 and has a negative forward P/E ratio of 0, which raises concerns about profitability. The RSI is at 46.487, suggesting it is neither overbought nor oversold, which aligns with a cautious approach.